Form 8-K - Current report:
SEC Accession No. 0001087294-26-000015
Filing Date
2026-03-03
Accepted
2026-03-03 17:10:28
Documents
14
Period of Report
2026-03-03
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cpix-20260303.htm   iXBRL 8-K 28670
2 EX-99.1 a2025q4ex991earningsrelease.htm EX-99.1 260818
6 GRAPHIC image_0a.jpg GRAPHIC 19195
  Complete submission text file 0001087294-26-000015.txt   456689

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cpix-20260303.xsd EX-101.SCH 1894
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cpix-20260303_lab.xml EX-101.LAB 21885
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cpix-20260303_pre.xml EX-101.PRE 12611
16 EXTRACTED XBRL INSTANCE DOCUMENT cpix-20260303_htm.xml XML 2723
Mailing Address 1600 WEST END AVENUE SUITE 1300 NASHVILLE TN 37203
Business Address 1600 WEST END AVENUE SUITE 1300 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

EIN.: 621765329 | State of Incorp.: TN | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33637 | Film No.: 26716296
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)